Home » Salix Pharmaceuticals Announces NDA Submission for Crofelemer for the Treatment of HIV-Associated Diarrhea
Salix Pharmaceuticals Announces NDA Submission for Crofelemer for the Treatment of HIV-Associated Diarrhea
Salix Pharmaceuticals announced that it has submitted to the FDA a new drug application for Crofelemer for the proposed treatment of HIV-associated diarrhea.
MarketWatch
MarketWatch
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May